Morgan Stanley Reaffirms "Hold" Rating for Keryx Biopharmaceuticals

Morgan Stanley Reaffirms "Hold" Rating for Keryx Biopharmaceuticals


's stock had its "hold" rating reaffirmed by equities researchers at Morgan Stanley in a note issued to investors on Saturday. Shares of Keryx Biopharmaceuticals traded up 0.83% during midday trading on Friday, hitting $6.05.



from Biotech News